Reuters: Celgene to buy Juno for $9 billion to boost cancer pipeline

2018-01-22 (31 Days Old)Total Views: 21 | Last 7 Days: 1

(Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid.